OPTHHealthcare · Drug Manufacturers - Specialty & Generic

OPTH Stock Forecast: Optimi Health Corp. Price Predictions for 2026-2027

Last close, 14 Sept 2026

$4.76

+7.69% on the day

Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 10 of 100 as at 12 Sept 2026 — in the weakest quartile.

Market cap

$25.3M

Ticker Nerd rank

10 / 100

Median analyst target

—

Analysts covering

—

Revenue$140K−28.6% y/y

Operating income−$2.1M

Net income−$2.4M

Free cash flow−$2.9M

Quarterly, 6 quarters to 30 June 2026 · latest quarter's figure shown

Total return, dividends reinvested

−0.4%

−0.6%

From high

−21.7%

From low

+18.7%

$4.01

$6.08

Range since 20 May 2026, adjusted closes · the dot is the last close

Ticker Nerd rank

OPTH stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Optimi Health Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 12 Sept 2026

10 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size

Revisions

Volatility

Momentum

Value

Growth

Accruals

Quality

Issuance

Size (87): Smaller than most of the companies we track.

Issuance (3): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

OPTH stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on OPTH, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, since 20 May 2026Adjusted close, US dollars

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. OPTH appears on the weeks it earns a place.

Performance

OPTH vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

OPTH vs S&P 500, last 12 monthsTotal return, rebased to 100

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

OPTH analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year

Analysts raising

Analysts cutting

Fundamentals

Optimi Health Corp. (OPTH) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation

Trailing P/E: −3.7×
Price / sales: 144.1×
Price / book: 2.0×
EV / EBITDA: −4.1×

Growth & margins

Revenue growth (YoY): −28.6%
Earnings growth (YoY): −28.6%
Gross margin: 47.5%
Operating margin: −957.8%
Net margin: −16.0%

Returns & dividend

Return on equity: −54.4%
Return on assets: −16.1%
Dividend yield: —

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Optimi Health Corp. (OPTH) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

Optimi Health Corp. has a market value of $25.3M and an enterprise value of $12.5M.
Revenue in the twelve months to 30 June 2026: $176K. The latest quarter shrank 28.6% year on year.
Net income over the same four quarters: −$6.9M, a −3927.6% net margin.
Free cash flow in the twelve months to 30 June 2026: −$5.3M, after $110K of capital spending.
Shares outstanding: 5.7M.
Trailing P/E: −3.7×.
Optimi Health Corp. employs 6 people — $29K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 13 Sept 2026

Data provided by Twelve Data

Peers

OPTH vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDrug Manufacturers - Specialty & Generic

Company	Market cap	TKN rank
OPTHOptimi Health Corp.	$25.3M	10
TXMDTherapeuticsMD, Inc.	$25.0M	80
BFRIBiofrontera, Inc.	$23.0M	67
UPCUniverse Pharmaceuticals, Inc.	$21.9M	34
RMTIRockwell Medical, Inc.	$31.4M	47
AYTUAytu Biopharma, Inc.	$21.4M	65
CPHIChina Pharma Holdings, Inc.	$32.7M	49

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Optimi Health Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest OPTH news & analysis

Optimi Health to Initiate Phase 2 Clinical Trial Evaluating Psilocybin-Assisted Therapy for Major Depressive Disorder

GlobeNewsWire · 10 Sept 2026positive

Optimi Health announced it will initiate a Health Canada-authorized Phase 2 clinical trial evaluating psilocybin-assisted therapy for major depressive disorder. The trial will assess a single supervised dose of natural psilocybin, with dosing expected to be completed by the end of 2027.

Why it matters — This milestone advances Optimi Health's clinical development in the psychedelic-assisted therapy space, potentially broadening its pipeline beyond its existing natural psilocybin production operations.

Optimi Health to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

GlobeNewsWire · 8 Sept 2026neutral

Optimi Health Corp. announced it will participate in the H.C. Wainwright 28th Annual Global Investment Conference. The commercial-stage pharmaceutical manufacturer of regulated psychedelic drug products will attend the upcoming investor event.

Why it matters — Participation in a major investment conference gives Optimi a platform to present its business to institutional investors and potentially raise its profile within the financial community.

Optimi Health Establishes Discretionary Equity Facility

GlobeNewsWire · 14 Aug 2026neutral

Optimi Health Corp. announced it entered into a common shares purchase agreement with Seven Knots, LLC, establishing a discretionary equity line of credit under which the Company has the right, but not the obligation, to sell up to US$100 million of its common shares over the term of the facility.

Why it matters — This facility gives Optimi access to potential financing of up to US$100 million on a discretionary basis, which watchers may see as relevant to the company's capital-raising flexibility and liquidity.

FAQ

Frequently asked questions about OPTH stock

How does Ticker Nerd's model rank OPTH?

As at 12 Sept 2026, Optimi Health Corp. ranks 10 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (87 of 100).

What is the OPTH stock forecast for 2030?

No analyst covering Optimi Health Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for OPTH are extrapolating price history, which says nothing about the business.

What does Optimi Health Corp. do?

Optimi Health Corp. is a Canadian pharmaceutical and nutraceutical manufacturer focused on controlled psychedelic drug products and functional mushrooms.

What is the latest news on OPTH?

The most recent item we track (GlobeNewsWire, 10 Sept 2026): "Optimi Health to Initiate Phase 2 Clinical Trial Evaluating Psilocybin-Assisted Therapy for Major Depressive Disorder". Optimi Health announced it will initiate a Health Canada-authorized Phase 2 clinical trial evaluating psilocybin-assisted therapy for major depressive disorder. The trial will assess a single supervised dose of natural psilocybin, with dosing expected to be completed by the end of 2027.

Company

About Optimi Health Corp.

Optimi Health Corp. is a Canadian pharmaceutical and nutraceutical manufacturer focused on controlled psychedelic drug products and functional mushrooms. The company produces finished-dose MDMA and psilocybin products, along with related ingredients and formulations used in regulated clinical and therapeutic programs. Its current business includes farming, processing, extraction, manufacturing, testing, and distribution of mushroom biomass, mushroom extracts, and supplements, serving authorized clinics, pharmacies, clinical trials, and health and wellness partners. Optimi Health Corp. also supplies botanical and pharmaceutical-grade psychedelic compounds for markets that require compliant, standardized production and traceability. Headquartered in Princeton, British Columbia, and incorporated in 2020, the company plays a specialized role in the emerging regulated market for psychedelic medicines and mushroom-based wellness products.

CEO Mr. Dane Stevens · 6 employees · Canada · https://www.optimihealth.ca